The estimated Net Worth of Leaf Venture Management Iii... is at least $63 Million dollars as of 15 August 2019. Leaf Iii owns over 350,000 units of Deciphera Pharmaceuticals Inc stock worth over $50,239,772 and over the last 7 years Leaf sold DCPH stock worth over $12,747,000.
Leaf has made over 2 trades of the Deciphera Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Leaf sold 350,000 units of DCPH stock worth $12,747,000 on 15 August 2019.
The largest trade Leaf's ever made was buying 375,000 units of Deciphera Pharmaceuticals Inc stock on 2 October 2017 worth over $6,375,000. On average, Leaf trades about 362,500 units every 341 days since 2017. As of 15 August 2019 Leaf still owns at least 1,963,258 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Leaf Iii stock trades at the bottom of the page.
Leaf's mailing address filed with the SEC is Manhattan, NY 10036, USA.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar und Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: